95882-32-9 Usage
Description
3-(1-METHYL-CYCLOHEXYL)-3-OXO-PROPIONITRILE is a chemical compound with the molecular formula C10H15NO and a molar mass of 165.23 g/mol. It is a nitrile derivative featuring a cyclohexyl ring and a ketone functional group, making it a key intermediate in the production of various pharmaceuticals, agrochemicals, and organic compounds.
Used in Pharmaceutical Industry:
3-(1-METHYL-CYCLOHEXYL)-3-OXO-PROPIONITRILE is used as a key intermediate for the synthesis of pharmaceutical ingredients. Its unique structure allows it to be a valuable building block in the development of new and effective medications.
Used in Agrochemical Industry:
3-(1-METHYL-CYCLOHEXYL)-3-OXO-PROPIONITRILE is used as a precursor in the production of agrochemicals, contributing to the development of innovative and efficient solutions for agricultural applications.
Used in Organic Chemicals Industry:
3-(1-METHYL-CYCLOHEXYL)-3-OXO-PROPIONITRILE is used as a building block in the synthesis of various organic compounds, playing a crucial role in the creation of useful and valuable products for a wide range of applications in the chemical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 95882-32-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,5,8,8 and 2 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 95882-32:
(7*9)+(6*5)+(5*8)+(4*8)+(3*2)+(2*3)+(1*2)=179
179 % 10 = 9
So 95882-32-9 is a valid CAS Registry Number.
95882-32-9Relevant articles and documents
PYRAZOLE P38 MAP KINASE INHIBITORS
-
Paragraph 0495-0496, (2013/03/26)
There are provided inter alia compounds of formula (I): wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.
Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate
Regan, John,Moss, Neil,Pargellis, Chris,Pav, Sue,Proto, Alfred,Swinamer, Alan,Tong, Liang,Torcellini, Carol,Breitfelder, Steffen,Cirillo, Pier,Gilmore, Thomas,Graham, Anne G.,Hickey, Eugene,Klaus, Bernhard,Madwed, Jeffrey,Moriak, Monica
, p. 2994 - 3008 (2007/10/03)
We report on a series of N-pyrazole, N′-aryl ureas and their mode of binding to p38 mitogen activated protein kinase. Importantly, a key binding domain that is distinct from the adenosine 5′-triphoshate (ATP) binding site is exposed when the conserved activation loop, consisting in part of Asp168-Phe169-Gly170, adopts a conformation permitting lipophilic and hydrogen bonding interactions between this class of inhibitors and the protein. We describe the correlation of the structure-activity relationships and crystallographic structures of these inhibitors with p38. In addition, we incorporated another binding pharmacophore that forms a hydrogen bond at the ATP binding site. This modification affords significant improvements in binding, cellular, and in vivo potencies resulting in the selection of 45 (BIRB 796) as a clinical candidate for the treatment of inflammatory diseases.
